SCHEMBL1325499

SCHEMBL1325499

c1ccc(C(c2ccccc2)[SiH](c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.39
TSHR P16473 2/20 0.39
F2 P00734 1/20 0.39
HTR2A P28223 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
CYP2D6 P10635 1/20 0.35
SRC P12931 1/20 0.35
LMNA P02545 2/20 0.33
HRH1 P35367 1/20 0.33
MTOR P42345 1/20 0.33
RAB9A P51151 1/20 0.33
GRM7 Q14831 1/20 0.33
MAPK1 P28482 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10319577 0.74 TSHR (0.48) DPP4TSHRF2HTR2ATAAR1
SCHEMBL15798275 0.69 KMT2A (0.37) DPP4TSHRF2HTR2ACYP2D6
SCHEMBL1325645 0.69 TDP1 (0.36) TSHRHTR2ATAAR1CYP2D6LMNA
SCHEMBL827249 0.69 ALDH1A1 (0.30)
SCHEMBL5614009 0.69 ALDH1A1 (0.30)
SCHEMBL2686473 0.69 TSHR (0.48) DPP4TSHRF2HTR2ATAAR1
SCHEMBL3894050 0.69 TSHR (0.44) DPP4TSHRF2CYP2D6SRC
SCHEMBL12815293 0.65 TSHR (0.38) TSHRTAAR1CYP2D6LMNASLC6A2
SCHEMBL15302723 0.65 TAAR1 (0.33) TSHRHTR2ATAAR1CYP2D6LMNA
SCHEMBL15302680 0.65 TDP1 (0.33) TSHRTAAR1CYP2D6LMNASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217060-B2 Benzimidazole derivatives useful as TRP M8 receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-07-10 US claimed
US-20100292276-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-11-18 US claimed
US-20230253626-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2023-08-10 US disclosed
US-20230051031-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2023-02-16 US disclosed
US-20230034883-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (60%) (IT) 2023-02-02 US disclosed
EP-4076730-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION Consiglio Nazionale Delle Ricerche (IT) 2022-10-26 EP disclosed
EP-4076729-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION Consiglio Nazionale Delle Ricerche (IT) 2022-10-26 EP disclosed
WO-2021124097-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2021-06-24 WO disclosed
WO-2021124103-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2021-06-24 WO disclosed
US-9926383-B2 Biocompatible three dimensional matrix for the immobilization of biological substances LEUKOCARE AG (DE) 2018-03-27 US disclosed
US-9206202-B2 Carbazole derivative and semiconductor nanocrystal RICOH COMPANY, LTD. (JP) 2015-12-08 US disclosed
US-20090269778-A1 BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES LEUKOCARE AG (DE) 2009-10-29 US disclosed
WO-2009059784-A1 BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES LEUKOCARE AG (DE) 2009-05-14 WO disclosed
EP-2058335-A1 Biocompatible three dimensional matrix for the immobilization of biological substances Leukocare AG (DE) 2009-05-13 EP disclosed
US-20090118222-A1 NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 US disclosed
EP-2045258-A1 3'-ETHYNYLCYTIDINE DERIVATIVE Taiho Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
EP-2021374-A1 BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES Leukocare AG (DE) 2009-02-11 EP disclosed
WO-2007128550-A1 BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES LEUKOCARE AG (DE) 2007-11-15 WO disclosed
EP-1852443-A1 Biocompatible three dimensional matrix for the immobilization of biological substances Leukocare AG (DE) 2007-11-07 EP disclosed
EP-1845102-A1 NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118222-A1 NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT CDK10, SRSF9, SNRPD1 DPP4 3389/4885TSHR 2261/4885F2 3366/4885
US-20100292276-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS TRPM8, TRPV1, TRPA1 DPP4 575/4885TSHR 2835/4885F2 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.